Towards optimization of cardiovascular stability in neonates with hypertrophic cardiomyopathy: uniqueness of the neonatal cardiovascular system.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Day-2 echocardiography and cardiovascular biomarkers measurements in neonates with hypoxic-ischemic encephalopathy with or without brain injury.Journal of perinatology : official journal of the California Perinatal Association · 2025
   Article
2. New insights in pediatrics in 2021: choices in allergy and immunology, critical care, endocrinology, gastroenterology, genetics, haematology, infectious diseases, neonatology, neurology, nutrition, palliative care, respiratory tract illnesses and telemedicine.Italian journal of pediatrics · 2022
   Review

Corrections and comments

• Comment on
  Use of vasopressin in neonatal hypertrophic obstructive cardiomyopathy: case series.2021
• Comment on
  Vasopressin in neonatal hypertrophic cardiomyopathy: do perceived benefits translate to clinical outcome?2021

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as